Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

By T. Ishizawa, K. Hasegawa, T. Aoki, Michiro Takahashi, Y. Inoue, K. Sano, H. Imamura, Y. Sugawara, N. Kokudo, M. Makuuchi. Gastroenterology, 2008

704 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/3c30fefc1ec5c5233cb10b1dba280834c8be099f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Jordi Bruix1 , 2
2. J. Llovet
3. V. Mazzaferro
4. Peter R. Galle
5. Andrew X. Zhu
6. Riccardo Lencioni
7. Alejandro Forner1 , 2
8. M. Kudo

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. Riccardo Lencioni
4. V. Mazzaferro
5. Alejandro Forner1 , 2
6. Andrew X. Zhu
7. María E. Reig1 , 2
8. Peter R. Galle

Citations in the corpus

• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “affecting survival in both surgical and medical patients with HCC in cirrhosis,(306) its relevance as an independent determinant of post-surgical outcomes has been questioned.(305) As limited resection in patients with preserved liver function and moderate CRPH yields competitive survival outcomes,(”
• Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects (2010, background): “In a study in surgical patients, we established that the presence of portal hypertension and increased bilirubin predicted a worse outcome as compared with patients without such findings even if limiting resection to Child–Pugh A patients.51 Accordingly, these parameters serve to predict survival in”
• Real‐time identification of liver cancers by using indocyanine green fluorescent imaging (2009, neutral): “More than 24 h 28 (85%) 22 (85%) Tumor size (mm)y 12 (2-40) 30 (7-150) <.”
• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “treatments are the mainstay strategy for HCC, LT is not recommended for Child–Pugh class A patients [411], and LR achieved 5-year survival rate of around 60% among Child–Pugh class A recipients even with portal hypertension [440], and when restricted to Child–Pugh class A patients within the Milan c”
• Hepatocellular carcinoma: a review (2016, background): “The reported rate of complete tumor necrosis in patients with tumors <3 cm was 90%.(91) The 2010 AASLD”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “This concept of portal hypertension as prognostic factor in patients undergoing resection has recently been validated in Asia [182].”
• Management of hepatocellular carcinoma: An update (2011, neutral): “Finally, the survival of those subjects with both adverse predictors (portal hypertension and elevated bilirubin) and/ or multifocal disease is less than 30% at 5 years, regardless of their Child–Pugh stage.(27,235) Therefore, measurement of portal pressure is a key step in the evaluation of candida”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “This concept of portal hypertension as prognostic factor in patients undergoing resection has recently been validated in Asia [182].”
• Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. (2014, neutral): “However, studies have suggested that if patients had preserved liver function, hepatic resection still achieved better survival results than nonsurgical treatments even for patients with multiple tumors.(43,44) In the present study, we showed that curative therapy achieved substantial survival benef”